Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Variants & evidence
522 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ABL1 H396R + ABL1 Fusion2 | |||||||
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID6988In a study of 39 chronic phase CML patients with BCR-ABL variants, H396R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID6258In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| ABL1 I432T + ABL1 Fusion1 | |||||||
| Bosutinib | Predictive | C | Supports Resistance | 2 | submitted | EID4562In a retrospective study of 288 imatinib-resistant or -intolerant, Philadelphia chromosome BCR-ABL1fusion positive, chronic myeloid leukemia (chronic phase) patients, a patient with the I432T mutation… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| ABL1 L248R + ABL1 Fusion3 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID7776In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Dasatinib + Imatinib MesylateSubstitutes | Predictive | D | Supports Resistance | 3 | accepted | EID6210In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC) PMID 15705718 · Burgess et al., 2005 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | D | Supports Resistance | 2 | accepted | ||
| ABL1 F359I + ABL1 L248R + ABL1 Fusion1 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID7775In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar sensitivity to axitinib in fusions with the L… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| ABL1 L248V + ABL1 Fusion10 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4311In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4310In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | submitted | EID4309In an in vitro study, a Ba/F3 murine cell line stably expressing the L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… | |
| ABL1 L364I + ABL1 Fusion3 | |||||||
| Dasatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4434Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the L364I secondary variant in 9/12 bacterial clones generated … (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4485In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 1 | accepted | EID7826One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later showed the BCR-ABL1 fusion with the L364I secondary varia… | |
| ABL1 L364I + ABL1 M244V + ABL1 Fusion1 | |||||||
| Dasatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID7943Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in myeloid blast crisis had the BCR-ABL1 fusion with M244V/L364I, M244V/L364I/N53S, M244V/L364I/M458T, L364I/… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| ABL1 L364P + ABL1 Fusion1 | |||||||
| Bosutinib | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4551In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| ABL1 L384M + ABL1 Fusion6 | |||||||
| Axitinib | Predictive | D | Does Not Support Resistance | 2 | accepted | EID4525In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4526In an in vitro study, a Ba/F3 murine cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with increased sensitivity to bosutinib treatment (… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | C | Supports Resistance | 1 | accepted | EID4527This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … | |
| ABL1 L387F + ABL1 Fusion4 | |||||||
| Bosutinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4553In a retrospective study of 288 imatinib-resistant or -intolerant, Philadelphia chromosome BCR-ABL1 fusion positive, chronic myeloid leukemia (chronic phase) patients, a patient with the L387F mutatio… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 1 | accepted | EID4552This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID6981In a study of 39 chronic phase CML patients with BCR-ABL variants, L387F was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … | |
| ABL1 L387M + ABL1 Fusion3 | |||||||
| Dasatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4406This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 3 | accepted | EID4407Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with L387M, L387M/F192L, and E450G variants in 7/10, 2/10, and 1/10 … (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4408In an in vitro study, a Ba/F3 cell line expressing a L387M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (2.0 nmol/L vs. 0.8 nmol/… | |
| ABL1 M244V + ABL1 Fusion14 | |||||||
| Axitinib | Predictive | D | Does Not Support Resistance | 2 | accepted | EID7771In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4307In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4308This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… | |
| ABL1 M343T + ABL1 Fusion1 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4534In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
Data updated 3 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)
PMID 16772610 · Bradeen et al., 2006 · Open in CIViC
| civic |
PMID 19075254 · Redaelli et al., 2009 · Open in CIViC
| civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6308This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 1 | accepted | EID7029In this phase II multinational study, 60 imatinib-resistantpatients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achie… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 2 | accepted | EID2642In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID2641A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID7044In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had L248V mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Dasatinib + Imatinib Mesylate + NilotinibSubstitutes | Predictive | D | Supports Resistance | 2 | accepted | EID2644In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| Imatinib Mesylate + NilotinibCombination | Predictive | D | Supports Resistance | 2 | accepted | EID6236In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 16775234 · Talpaz et al., 2006 · Open in CIViC
| civic |
PMID 19779040 · Müller et al., 2009 · Open in CIViC
| civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4528In an in vitro study, Ba/F3 cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 4.04 … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 2 | submitted | EID7824One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the F486S secondary variant in 2/11 clones had partial best cytogenetic response to imatinib before becoming complete… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| Imatinib Mesylate + NilotinibSubstitutes | Predictive | D | Supports Resistance | 1 | accepted | EID2861In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 22371878 · Khoury et al., 2012 · Open in CIViC
| civic |
| Nilotinib | Predictive | D | Supports Resistance | 2 | accepted | EID2863In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fu… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 15930265 · O'Hare et al., 2005 · Open in CIViC
| civic |
PMID 22371878 · Khoury et al., 2012 · Open in CIViC
| civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID4302This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID4303In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the A… (full text at CIViC) PMID 19487385 · Apperley et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4305Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M244V secondary variant in 12/12 bacterial clones generated… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4304In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achi… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4306In an in vitro study, a Ba/F3 cell line expressing an M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.3 nmol/L vs. 0.8… (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC | civic |
| Imatinib | Predictive | C | Does Not Support Resistance | 3 | accepted | EID2636In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had only a partial … (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 1 | accepted | EID7825One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later revealed the BCR-ABL1 fusion with the M244V secondary var… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 2 | accepted | EID6994In a study of 39 chronic phase CML patients with BCR-ABL variants, M244V was seen in 3 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine … (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 1 | accepted | EID7042In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had M244V mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID6242In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| Nilotinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID2639A chronic myelogenous leukemia patient with a M244V mutation in the ABL1 portion of the BCR-ABL1 fusion was associated with response to nilotinib monotherapy. Prior to detection of the M244V mutation,… (full text at CIViC) PMID 26622510 · Shen et al., 2015 · Open in CIViC | civic |